Brief: Matinas Biopharma Announces Positive Interim Data From The Phase 2 Enact Trial Of Mat2203

Matinas BioPharma Holdings

21/10/2022 13:01

Oct 21 (Reuters) - Matinas BioPharma Holdings Inc
 MTNB.A :
    * MATINAS BIOPHARMA ANNOUNCES POSITIVE INTERIM DATA FROM THE
PHASE
2 ENACT TRIAL OF MAT2203 FOR THE TREATMENT OF CRYPTOCOCCAL
MENINGITIS, EXCEEDING PRIMARY ENDPOINT THRESHOLD; PATIENT
SURVIVAL IN ALL-ORAL COHORT 4 REGIMEN CURRENTLY 90%
    * MATINAS BIOPHARMA HOLDINGS INC - PHASE 3 REGISTRATION
TRIAL OF
MAT2203 FOR TREATMENT OF CRYPTOCOCCAL MENINGITIS TO COMMENCE Q1
2023
    * MATINAS BIOPHARMA- FAVORABLE SAFETY, TOLERABILITY DATA
SUPPORT
LONGER-TERM USE OF MAT2203 WITH NO EVIDENCE OF KIDNEY TOXICITY
SEEN WITH 6 WEEKS OF ORAL MAT2203 TREATMENT
    * MATINAS BIOPHARMA - OVERALL SURVIVAL DATA FROM COHORTS 2
AND 4
OF ENACT TRIAL PROVIDE CLINICALLY MEANINGFUL EVIDENCE OF SAFETY
AND EFFICACY OF MAT2203

Source text for Eikon:  ID:nGNX2vVH9f 
Further company coverage:  MTNB.A 
 ((Reuters.Briefs@thomsonreuters.com;))